Latest news from Covid-19 Prevention Network (CoVPN) on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/coordination-of-covid-19-vaccine-clinical-trials-produces-a-treasure-trove-of-data-and-a-model-for-the-future/?sc=rsin /articles/coordination-of-covid-19-vaccine-clinical-trials-produces-a-treasure-trove-of-data-and-a-model-for-the-future/?sc=rsin Mon, 23 Jan 2023 17:05:12 EST The federally funded COVID-19 Prevention Network was instrumental in the rapid development of safe, effective and lifesaving COVID-19 vaccines during earlier phases of the pandemic. This vital work to expedite Phase 3 clinical trials also resulted in a 'treasure trove' of data, thanks to a highly collaborative and harmonized approach that can serve as a national and even international model for major research initiatives while also guiding responses to future public health emergencies. Covid-19 Prevention Network (CoVPN) /articles/covpn-trial-novavax-s-traditional-covid-19-vaccine-correlates-to-strong-antibody-response-protection-against-sars-cov-2/?sc=rsin /articles/covpn-trial-novavax-s-traditional-covid-19-vaccine-correlates-to-strong-antibody-response-protection-against-sars-cov-2/?sc=rsin Tue, 28 Jun 2022 11:05:42 EST A new analysis of the Novavax PREVENT-19 clinical trial concluded that this recombinant protein vaccine produced an antibody response comparable to mRNA vaccines and, if authorized, could help bolster global vaccine supplies. This is the first study to directly support antibody correlates of protection for a recombinant protein COVID-19 vaccine. Covid-19 Prevention Network (CoVPN) /articles/preliminary-findings-from-studies-in-south-africa-indicate-that-omicron-has-a-much-higher-rate-of-asymptomatic-carriage-than-other-variants-of-concern/?sc=rsin /articles/preliminary-findings-from-studies-in-south-africa-indicate-that-omicron-has-a-much-higher-rate-of-asymptomatic-carriage-than-other-variants-of-concern/?sc=rsin Fri, 07 Jan 2022 08:00:54 EST Preliminary findings from two clinical trials in South Africa suggest that the omicron variant of the virus that causes COVID-19 may have a much higher rate of asymptomatic 'carriage' than earlier variants. This higher asymptomatic carriage rate is likely a major factor in the rapid and widespread dissemination of the variant, even among populations with high prior rates of coronavirus infection. Covid-19 Prevention Network (CoVPN) /articles/landmark-covid-19-vaccine-trial-in-sub-saharan-africa-is-the-first-to-study-the-efficacy-of-mrna-covid-19-vaccines-in-people-living-with-hiv/?sc=rsin /articles/landmark-covid-19-vaccine-trial-in-sub-saharan-africa-is-the-first-to-study-the-efficacy-of-mrna-covid-19-vaccines-in-people-living-with-hiv/?sc=rsin Mon, 13 Dec 2021 13:25:29 EST A highly anticipated clinical trial in eight sub-Saharan countries is the first to specifically evaluate the efficacy of a COVID-19 vaccine in people living with HIV, including those with poorly controlled infections. It also is the first study to evaluate the efficacy of vaccines - in this case, Moderna mRNA-1273 - against the omicron variant of SARS-CoV-2, the virus that causes COVID-19. Covid-19 Prevention Network (CoVPN) /articles/new-study-demonstrates-community-engagement-efforts-are-critical-to-ensuring-the-equitable-inclusion-of-bipoc-communities-in-vaccine-clinical-trials/?sc=rsin /articles/new-study-demonstrates-community-engagement-efforts-are-critical-to-ensuring-the-equitable-inclusion-of-bipoc-communities-in-vaccine-clinical-trials/?sc=rsin Tue, 19 Oct 2021 16:35:49 EST A team of research experts from the COVID-19 Prevention Network (CoVPN), headquartered at Fred Hutchinson Cancer Research Center, has demonstrated that through robust community engagement, equitable inclusion in vaccine clinical trials can make a powerful impact in the health of underrepresented communities. Covid-19 Prevention Network (CoVPN) /articles/study-testing-how-well-covid-19-vaccine-prevents-infection-and-spread-of-sars-cov-2-among-university-students-now-expands-to-include-young-adults-beyond-the-university-setting/?sc=rsin /articles/study-testing-how-well-covid-19-vaccine-prevents-infection-and-spread-of-sars-cov-2-among-university-students-now-expands-to-include-young-adults-beyond-the-university-setting/?sc=rsin Tue, 22 Jun 2021 12:00:00 EST The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine. Covid-19 Prevention Network (CoVPN) /articles/new-clinical-trial-will-test-if-covid-19-vaccine-prevents-infection-and-spread-of-sars-cov-2-among-college-students/?sc=rsin /articles/new-clinical-trial-will-test-if-covid-19-vaccine-prevents-infection-and-spread-of-sars-cov-2-among-college-students/?sc=rsin Fri, 26 Mar 2021 11:30:32 EST A new CoVPN study evaluating SARS-CoV-2 infection and transmission among college students vaccinated with the Moderna COVID-19 vaccine was announced today. The new trial will tell us whether a person can become infected after they've been vaccinated and if the vaccine will stop the virus from spreading person-to-person. Covid-19 Prevention Network (CoVPN) /articles/covpn-s-faith-and-diversity-work-engages-key-communities-impacted-by-covid-19/?sc=rsin /articles/covpn-s-faith-and-diversity-work-engages-key-communities-impacted-by-covid-19/?sc=rsin Thu, 11 Mar 2021 08:05:21 EST The COVID-19 Prevention Network (CoVPN) released today the CoVPN Faith Initiative and Diversity Report, which provides a snapshot of key work to build trust, inform and engage the communities hardest hit by the pandemic in conversations about faith, COVID-19 and CoVPN clinical trials. Covid-19 Prevention Network (CoVPN)